Relation of baseline high-sensitivity c-reactive protein level to cardiovascular outcomes with rosuvastatin in the justification for use of statins in prevention: An intervention trial evaluating rosuvastatin (JUPITER)

American Journal of Cardiology

Volumn 106, Issue 2, 2010, Pages 204-209

  Ridker, Paul M ^a,b   MacFadyen, Jean ^a   Libby, Peter ^b   Glynn, Robert J ^a  

^a Center for Cardiovascular Disease Prevention   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT OUTCOME;

C-REACTIVE PROTEIN; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRIMARY PREVENTION; PYRIMIDINES; RISK FACTORS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 77955711541     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.03.018     Document Type: Article

References (8)

1. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen, B.G. Nordestgaard, J. Shepherd, J.T. Willerson, and R.J. Glynn Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
2. R.J. Glynn, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen, B.G. Nordestgaard, J. Shepherd, J.T. Willerson, and P.M. Ridker A randomized trial of rosuvastatin in the prevention of venous thromboembolism N Engl J Med 360 2009 1851 1861
3. The Emerging Risk Factors Collaboration C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis Lancet 375 2010 132 140
4. J. Genest, R. McPherson, J. Frohlich, T. Anderson, N. Campbell, A. Carpentier, P. Couture, R. Dufour, G. Fodor, G.A. Francis, S. Grover, M. Gupta, R.A. Hegele, D.C. Lau, L. Leiter, G.F. Lewis, E. Lonn, G.B. Mancini, D. Ng, G.J. Pearson, A. Sniderman, J.A. Stone, and E. Ur 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations Can J Cardiol 25 2009 567 579
5. E.D. Michos, and R.S. Blumenthal Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study J Am Coll Cardiol 53 2009 931 935
6. E.Y. Yang, V. Nambi, Z. Tang, S.S. Virani, E. Boerwinkle, R.C. Hoogeveen, B.C. Astor, T.H. Mosley, J. Coresh, L. Chambless, and C.M. Ballantyne Clinical implications of JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) in a U.S. population: insights from the ARIC (Atherosclerosis Risk In Communities) Study J Am Coll Cardiol 54 2009 2388 2395
7. P.M. Ridker, N. Rifai, L. Rose, J.E. Buring, and N.R. Cook Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 2002 1557 1565
8. P.M. Ridker, C.P. Cannon, D. Morrow, N. Rifai, L.M. Rose, C.H. McCabe, M.A. Pfeffer, E. Braunwald Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVEIT - TIMI 22) Investigators C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28